ATE486945T1 - Vektoren mit erhöhter expression, sowie verfahren zu deren herstellung und deren verwendungen - Google Patents
Vektoren mit erhöhter expression, sowie verfahren zu deren herstellung und deren verwendungenInfo
- Publication number
- ATE486945T1 ATE486945T1 AT04075152T AT04075152T ATE486945T1 AT E486945 T1 ATE486945 T1 AT E486945T1 AT 04075152 T AT04075152 T AT 04075152T AT 04075152 T AT04075152 T AT 04075152T AT E486945 T1 ATE486945 T1 AT E486945T1
- Authority
- AT
- Austria
- Prior art keywords
- factor
- nucleic acid
- transcription factor
- reading frame
- open reading
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Image Generation (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/816,155 US5990091A (en) | 1997-03-12 | 1997-03-12 | Vectors having enhanced expression, and methods of making and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE486945T1 true ATE486945T1 (de) | 2010-11-15 |
Family
ID=25219820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04075152T ATE486945T1 (de) | 1997-03-12 | 1998-02-13 | Vektoren mit erhöhter expression, sowie verfahren zu deren herstellung und deren verwendungen |
Country Status (9)
Country | Link |
---|---|
US (2) | US5990091A (de) |
EP (2) | EP1475443B1 (de) |
JP (2) | JP2001514518A (de) |
AT (1) | ATE486945T1 (de) |
AU (1) | AU746402B2 (de) |
CA (1) | CA2283537C (de) |
DE (1) | DE69841986D1 (de) |
DK (1) | DK1475443T3 (de) |
WO (1) | WO1998040501A1 (de) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
ATE281844T1 (de) * | 1998-01-16 | 2004-11-15 | Univ Johns Hopkins | Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe |
US6762038B1 (en) * | 1998-09-09 | 2004-07-13 | The Cleveland Clinic Foundation | Mutant cell lines and methods for producing enhanced levels of recombinant proteins |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
WO2001045735A2 (en) * | 1999-12-21 | 2001-06-28 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
CA2416725A1 (en) * | 2000-04-27 | 2001-11-08 | Aventis Pasteur Limited | Immunizing against hiv infection |
DK1282702T3 (da) | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
US20110091428A1 (en) * | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
US7547674B2 (en) * | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
CA2416893A1 (en) * | 2000-07-31 | 2002-02-07 | Aventis Pasteur Limited | Modified cea and uses thereof |
US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
AU2001284695A1 (en) * | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
EP1317281A1 (de) * | 2000-09-08 | 2003-06-11 | Aventis Pasteur | Verwendung fon lipopeptiden zur behandlung von hiv-patienten |
FR2813793B1 (fr) * | 2000-09-08 | 2003-01-24 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
AU2001291225A1 (en) | 2000-09-26 | 2002-04-08 | Health Research Incorporated | Analysis of hiv-1 coreceptor use in the clinical care of hiv-1-infected patients |
CA2443266A1 (en) * | 2001-02-13 | 2002-08-22 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
WO2002070695A2 (en) * | 2001-03-05 | 2002-09-12 | Mount Sinai Hospital | Tumor associated proteins |
FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
DE10144664B4 (de) * | 2001-09-11 | 2005-06-09 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
WO2003063770A2 (en) | 2001-11-07 | 2003-08-07 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
US20050019752A1 (en) * | 2001-11-16 | 2005-01-27 | Genoveffa Franchini | Novel chimeric rev, tat, and nef antigens |
AU2002364161A1 (en) * | 2001-12-12 | 2003-06-23 | Aventis Pasteur Limited | Enhancement of the immune response using cd36-binding domain |
US20040241723A1 (en) * | 2002-03-18 | 2004-12-02 | Marquess Foley Leigh Shaw | Systems and methods for improving protein and milk production of dairy herds |
US7786278B2 (en) * | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US6952160B1 (en) * | 2002-08-07 | 2005-10-04 | Ford Global Technologies, Llc | Method and apparatus, for identifying the location of pressure sensors in a tire pressure monitoring system |
US7473536B2 (en) | 2002-08-07 | 2009-01-06 | Bavarian Nordic A/S | Isolated avian cell that expresses Vaccinia virus host range genes |
EP1903056A3 (de) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon |
US20040170646A1 (en) * | 2002-12-13 | 2004-09-02 | Aventis Pasteur, Inc. | Production of ALVAC on avian embryonic stem cells |
JP5052893B2 (ja) * | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
EP2390352A1 (de) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren |
WO2004094454A2 (en) | 2003-04-18 | 2004-11-04 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
EP1689858B1 (de) | 2003-11-13 | 2013-05-15 | University Of Georgia Research Foundation, Inc. | Verfahren zur charakterisierung des ibd (infectious bursal disease)-virus |
US20050202484A1 (en) | 2004-02-19 | 2005-09-15 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
US7342107B2 (en) * | 2004-05-27 | 2008-03-11 | Centocor, Inc. | Cynomolgus prostate specific antigen |
CA2570563A1 (en) * | 2004-06-15 | 2006-09-28 | Centocor, Inc. | Method for screening agents against human prostate disease |
JP5449673B2 (ja) | 2004-10-08 | 2014-03-19 | クリヌベール、ファーマスーティカルズ、リミテッド | 対象者におけるメラニン形成を誘導するための組成物および方法 |
CN101208104B (zh) | 2005-04-25 | 2012-10-31 | 梅瑞尔有限公司 | Nipah病毒疫苗 |
JP2009512421A (ja) | 2005-08-15 | 2009-03-26 | ヴァクシン インコーポレイテッド | 非複製性ベクターワクチン投与による鳥類への免疫方法 |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
WO2007056614A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
US20090060947A1 (en) * | 2006-05-19 | 2009-03-05 | Sanofi Pasteur, Inc. | Immunological compositions |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
EP2056854A4 (de) * | 2006-08-28 | 2011-09-14 | Clinuvel Pharmaceuticals Ltd | Verfahren zur reduzierung der inzidenz oder rate der entstehung von hautkrebs und verwandter erkrankungen |
ES2525476T3 (es) | 2006-08-31 | 2014-12-23 | Clinuvel Pharmaceuticals Limited | Derivados de alfa-MSH para el tratamiento de fotodermatosis |
WO2008148068A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
WO2009062143A2 (en) * | 2007-11-09 | 2009-05-14 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof |
BRPI0908474A2 (pt) | 2008-02-12 | 2016-07-26 | Sanofi Pasteur Ltd | métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora |
SI2957292T1 (en) * | 2008-03-27 | 2018-04-30 | Clinuvel Pharmaceuticals Limited | Vitiligo therapy |
MX2011006922A (es) | 2008-12-24 | 2012-06-12 | Netherlands Vaccine Inst | Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia. |
EP2998315B2 (de) | 2009-04-03 | 2021-11-03 | Boehringer Ingelheim Animal Health USA Inc. | Auf das virus der newcastle-krankheit gerichtete avianvirus-impfstoffe |
US9670506B2 (en) | 2009-04-30 | 2017-06-06 | Consejo Superior De Investigaciones Cientificas | Modified immunization vectors |
PL2611460T3 (pl) | 2010-08-31 | 2017-02-28 | Merial, Inc. | Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle |
WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
WO2012101509A2 (en) | 2011-01-28 | 2012-08-02 | Sanofi Pasteur Sa | Immunological compositions against hiv |
EP2487185A1 (de) | 2011-02-11 | 2012-08-15 | Clinuvel Pharmaceuticals Limited | Hexapeptid mit verbesserter Aktivität bei der Reparatur von zellulärer DNA von Dermiszellen |
WO2012129295A1 (en) | 2011-03-21 | 2012-09-27 | Vaxin Inc. | Rapid and prolonged immunologic-therapeutic |
US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
CA2834288A1 (en) | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
ES2674439T3 (es) | 2011-06-01 | 2018-06-29 | Merial, Inc. | Administración sin aguja de vacunas contra el VSRRP |
WO2013022991A2 (en) | 2011-08-08 | 2013-02-14 | Curelab Oncology, Inc. | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
DK2741740T3 (en) | 2011-08-12 | 2017-06-06 | Merial Inc | VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
WO2014012090A1 (en) | 2012-07-13 | 2014-01-16 | The Broad Institute, Inc. | Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof |
KR101484605B1 (ko) | 2012-07-25 | 2015-01-20 | 대한민국 | Bei로 불활화된 일본뇌염 바이러스 kv1899주 항원 및 돼지의 gm-csf 재조합 단백질을 포함하는 일본뇌염 불활화 백신 조성물 |
EP3808844A1 (de) | 2012-07-25 | 2021-04-21 | The Broad Institute, Inc. | Induzierbare dns-bindende proteine und genomperturbationswerkzeuge und deren anwendungen |
EP2968514A1 (de) | 2013-03-12 | 2016-01-20 | Merial, Inc. | Mittels reverser genetik hergestellte impfstoffzusammensetzungen gegen schmallenberg-virus und verfahren zur verwendung davon |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
JP6821429B2 (ja) | 2013-09-25 | 2021-01-27 | ゾエティス・サービシーズ・エルエルシー | Pcv2b分岐ワクチン組成物及び使用方法 |
WO2015057671A1 (en) | 2013-10-14 | 2015-04-23 | The Broad Institute, Inc. | Artificial transcription factors comprising a sliding domain and uses thereof |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
RU2016128557A (ru) | 2013-12-29 | 2018-02-01 | Кьюрлаб Онколоджи, Инк. | МЕТОДЫ И КОМПОЗИЦИИ, СВЯЗАННЫЕ С p62 / SQSTM1, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ВОСПАЛЕНИЕМ |
US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
EP3234130B1 (de) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Verfahren zum profiling vom t-zell-rezeptor-repertoire |
EP3234193B1 (de) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molekulare biomarker für krebsimmuntherapie |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
CA2990643C (en) | 2015-06-23 | 2023-10-17 | Merial, Inc. | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20230295644A1 (en) * | 2018-10-10 | 2023-09-21 | Bioleaders Corporation | Surface expression vector using two kinds of promoters derived from lactobacillus casei for concurrently expressing two target proteins and method for expressing proteins on microbial surface by using same |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2023277069A1 (ja) * | 2021-06-30 | 2023-01-05 | 株式会社レプリテック | マイナス鎖rnaウイルスベクターの製造方法および製造されたマイナス鎖rnaウイルスベクター |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4738922A (en) * | 1984-05-25 | 1988-04-19 | Dana Farber Cancer Institute | Trans-acting transcriptional factors |
US5302517A (en) * | 1987-06-16 | 1994-04-12 | The Board Of Regents Of The University Of Nebraska | Method of controlling the expression of a gene in a cell culture, cell culture vector used in the method and method of making the vector |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
CA1307482C (en) * | 1987-11-09 | 1992-09-15 | Ronald G. Schoner | Vectors and expression sequences for production of polypeptides |
US5192669A (en) * | 1987-11-09 | 1993-03-09 | Eli Lilly And Company | Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences |
WO1990001550A1 (en) * | 1988-07-29 | 1990-02-22 | Zymogenetics, Inc. | High efficiency translation of polycistronic messages in eucaryotic cells |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
EP1156102A1 (de) * | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Rekombinanter hiv-spezifischer Impfstoff aus Poxvirus |
JPH0638773A (ja) * | 1992-01-31 | 1994-02-15 | Toyobo Co Ltd | 薬剤耐性構造タンパク質遺伝子を選択遺伝子として用いた発現ベクター |
JPH06277074A (ja) * | 1993-03-31 | 1994-10-04 | Terumo Corp | 発現ベクター |
GB2299336A (en) * | 1993-12-23 | 1996-10-02 | Merck & Co Inc | Homologous recombination antibody expression sysstem for murine cells |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
EP1840209A3 (de) * | 1995-01-13 | 2008-03-05 | Virogenetics Corporation | Adeno-assoziierten Virusvektoren und deren Verwendung. |
-
1997
- 1997-03-12 US US08/816,155 patent/US5990091A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 DK DK04075152.1T patent/DK1475443T3/da active
- 1998-02-13 AT AT04075152T patent/ATE486945T1/de not_active IP Right Cessation
- 1998-02-13 CA CA002283537A patent/CA2283537C/en not_active Expired - Lifetime
- 1998-02-13 EP EP04075152A patent/EP1475443B1/de not_active Expired - Lifetime
- 1998-02-13 AU AU61584/98A patent/AU746402B2/en not_active Ceased
- 1998-02-13 EP EP98906338A patent/EP0970226A4/de not_active Withdrawn
- 1998-02-13 JP JP53956498A patent/JP2001514518A/ja active Pending
- 1998-02-13 DE DE69841986T patent/DE69841986D1/de not_active Expired - Lifetime
- 1998-02-13 WO PCT/US1998/002669 patent/WO1998040501A1/en not_active Application Discontinuation
- 1998-05-15 US US09/079,587 patent/US6130066A/en not_active Expired - Lifetime
-
2008
- 2008-08-21 JP JP2008212589A patent/JP5405780B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6130066A (en) | 2000-10-10 |
JP5405780B2 (ja) | 2014-02-05 |
EP0970226A4 (de) | 2002-06-12 |
WO1998040501A1 (en) | 1998-09-17 |
US5990091A (en) | 1999-11-23 |
DE69841986D1 (de) | 2010-12-16 |
AU6158498A (en) | 1998-09-29 |
EP1475443A2 (de) | 2004-11-10 |
EP0970226A1 (de) | 2000-01-12 |
CA2283537C (en) | 2009-04-28 |
JP2001514518A (ja) | 2001-09-11 |
CA2283537A1 (en) | 1998-09-17 |
EP1475443A3 (de) | 2004-12-01 |
DK1475443T3 (da) | 2011-02-21 |
EP1475443B1 (de) | 2010-11-03 |
AU746402B2 (en) | 2002-05-02 |
JP2008307056A (ja) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE486945T1 (de) | Vektoren mit erhöhter expression, sowie verfahren zu deren herstellung und deren verwendungen | |
DE69839554D1 (de) | Vektoren mit erhöhter expression, sowie verfahren zu deren herstellung und deren verwendungen | |
DE69928263D1 (de) | Verfahren zur herstellung in vitro von rekombinierten nucleotidsequenzen, und so hergestelte genbanken und sequenzen | |
ATE233273T1 (de) | Herstellung synthetischer dns und deren verwendung bei der synthese grosser polypeptide | |
DK0637342T3 (da) | Fremgangsmåde til typebestemmelse af HCV-isolater | |
DK496485D0 (da) | Transformation af gaer-stammer af slaegten pichia | |
EP0341473A3 (de) | Verfahren zur Sulfonierung von aromatischen Polyäthersulfonen und sulfonierte aromatische Polyäthersulfone | |
BR8301918A (pt) | Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase | |
FI970200A (fi) | Termofiilinen sieniekspressiojärjestelmä | |
DE3783191D1 (de) | Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g. | |
WO2000006726A3 (en) | Delta-related polypeptides | |
PT80901A (de) | Neue genetische sequenzen die durch sie codierten interferon-peptide von typ i und diese sie produzierende organismen | |
BR0215003A (pt) | Método para a recuperação e purificação de poxvìrus a partir de células infectadas | |
EP0207402A3 (de) | Verfahren zur Herstellung von Proteinen und Polypeptiden | |
NO930979D0 (no) | Flekkbestandig beleggsmateriale | |
PT97383A (pt) | Processo para a producao de uma cadeia de globina, de um seu fragmento de ligacao e de hemoglobina, e de composicoes de hemoglobina | |
DE69711579T2 (de) | Verfahren zur Herstellung von sehr reinem Isobuten, das eine Hydroisomerisierung in Reaktivdistillation und eine Kohlenstoffgerüstisomerisierung kombiniert | |
DE3888386D1 (de) | Verfahren zur Herstellung von Proteinen. | |
Grossenbacher et al. | Isolation and characterization of recombinant desulfatohirudin from yeast, a highly selective thrombin inhibitor | |
ES2111537T3 (es) | Inhibidor de la ribonucleasa de placenta humana recombinante y metodo de produccion. | |
Hörmann et al. | Affinity chromatography of fibrinogen plasminolysis fragment D | |
McDermott et al. | Purification of a 43 000 Dalton aggregate generated from α-crystallin | |
KR960001120A (ko) | 인간 플레이오트로핀 유전자의 발현벡터 및 효모에서의 인간 플레이오트로핀 단백질의 제조방법 | |
ATE183237T1 (de) | Mikrobielle herstellung von 5-ketogluconat | |
ATE420962T1 (de) | Rekombinante n-proteinase, deren herstellung, methoden und anwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |